Objectives. To gain updated estimates of prevalence and incidence of RA and proportion on biological treatment in southern Sweden.
Introduction
RA is a key chronic rheumatic disease imposing a great burden on individuals and society accentuated by the introduction of new expensive targeted biological treatments during the last decade [1] . A wide variety of studies have provided estimates of its occurrence [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . In a study performed in 1995, the prevalence of RA in Sweden was estimated to be 0.51% [4] . However, there are reports suggesting that the occurrence of RA is declining [3, 15] . Thus, we are in need of updated estimates using cost-and time-effective and reproducible methods. So far, most estimates of disease occurrence are obtained from studying a subsample of a population using often costly examinations or surveys prone to selection bias, not in the least patient induced [16] . An alternative approach is to use information from population-based health care registers. These registers can capture persons who seek health care for their symptoms or for treatment monitoring and such registers may thus, depending on the setting, represent a good measure of clinically important disease. The potential of observational data from registers to provide measures of disease occurrence and evidence in a timely manner has recently received increased attention [17] .
Swedish inpatient health care register data have been used for research and quality assurance, e.g. The Swedish Knee Arthroplasty Register [18] , but the utilization of combined inpatient and outpatient data in Sweden is novel. The health care data are suitable for the study of disease occurrence due to the public health care system where all residents are entitled to free health care and all health care providers are required to submit information for reimbursement purposes ensuring high-quality reporting. Also, by cross-referencing with treatment registers we can obtain basic epidemiological information on prescription patterns for biological treatment [19] .
Thus, our objective was to estimate the prevalence and incidence of RA that have led to health care utilization in a well-defined geographical region, and to relate this to prescribed biological treatment. We extracted data from the Skå ne Health Care Register (SHCR) covering 1.2 million inhabitants. We made assumptions based on the loss of patients seen only by four private rheumatologists (whose diagnoses have so far not been forwarded to the SHCR) and tested the effects on the estimates in a series of sensitivity analyses. Use of biologics was extracted from the register held by the South Swedish Arthritis Treatment Group (SSATG).
Methods
The Swedish health care system
The Swedish health care system is basically funded by city council tax and state grants. According to health and medical care policy, every county council must provide residents with equally good-quality health services and medical care. Similar low co-pay applies for both public and private health care providers, all with the same tax-based financing system. Thus, the choice between a public or private health care provider is often based on convenience, not on social class or income, and it is common for a person to have both a public and a private record of health care. Referrals can for example go from a public primary care clinic to a specialist in private practice, or from a private primary care facility to a specialist practising in public care. By law, all health care provided has to be registered by the patient's unique 10-digit personal identification number, which is automatically assigned to all residents and provides information on date of birth and sex.
The Skå ne Health Care Register
The county of Skå ne located in the southernmost part of Sweden is one of the largest county councils and contains both rural and urban areas. Its population, 1 214 758 inhabitants as on 31 December 2008 (predominantly Caucasian), accounts for one-eighth of the Swedish population. All levels of health care (i.e. from primary outpatient care to highly specialized in-hospital care) are represented in the county, and residents are listed to a primary care physician in their district of residence. Furthermore, health care provision at consultant level outside the county would normally require a special and restricted permission procedure, thus we expect there to be a negligible volume of health care provided outside the county.
Each single health care consultation (public and private) generates data entries by the health care provider that are transferred to central databases. These entries constitute the basis for reimbursement. Similar regulations for reporting of data to the county council and governmental authorities apply for private care providers but diagnoses in private care are not reported to the SHCR (future plans are to have these diagnoses registered as well). Since 1997, diagnoses have been classified according to the Swedish translation of the International Classification of Diseases and Related Health Problems (ICD)-10 system (http://www.who.int/classifications/icd/en/index.html).
The Swedish population register
The population register is the civil registration of vital events (e.g. births, deaths, marriages and change of residential address) of all inhabitants of Sweden. The register is continuously updated and is used for a variety of purposes including tax purposes and voting records not only by official authorities but also by service institutions such as banks and health care providers.
Case definition
In Sweden, as elsewhere, the diagnosis of RA relies on clinical judgement. However, primary care physicians almost always refer a patient with RA symptoms to a rheumatologist, since the importance of efficacious and available treatments is widely accepted in the medical community [4] . The regular reporting to national and regional RA registries for >10 years has made Swedish rheumatologists well aware of the ACR 1987 classification criteria, and they often use them to test the accuracy of their clinical diagnosis [20] . Further, modern RA treatment requires regular visits to determine and monitor treatments. Therefore, to increase specificity for RA we applied a case criterion requiring the diagnosis of seropositive or other RA (M05 or M06, Table 1 ) on at least two separate occasions, whereof at least one should be given by a specialist (or under specialty training) in rheumatology or internal medicine.
Point prevalence estimates as on 31 December 2008
Using data from the SHCR in the period from 1 January 2003 to 31 December 2008 (six calendar years), we applied the criteria (as detailed above) to identify all patients diagnosed with RA. We required all cases to be aged 520 years and linked data to the population register to exclude those who had died or were no longer resident in the county by the end of 2008. All identified patients were considered to have RA diagnosis for life, because of the chronic nature of this disease.
Due to the loss of cases seen only by private practitioners (whose diagnoses were not forwarded to the central databases, only that the visit occurred) we needed to adjust the total population (931 316 inhabitants aged 520 years) in the calculation of the estimates. While private practitioners in primary care were responsible for close to one-third of the total amount of outpatient consultations in the county during this period, there were only four private rheumatologists in the county (there were in total 52 specialists or physicians under specialty training in rheumatology practising in public health care by the end of 2008). Thus, we needed to estimate the share of RA patients regularly seen by these private practitioners. We cross-referenced SHCR data with the register held by the SSATG [21] . Hence, we determined the share of RA patients (98% fulfilling ACR classification criteria [22] ), who were aged 520 years, were alive and resident in the county, and had ever been treated with biologics (etanercept, infliximab, adalimumab, anakinra, abatacept or andrituximab with treatment start 17 November 2008 or earlier), but had not been captured in the SHCR according to our case definition [106 out of 1455 (7.3%)]. Based on these analyses, we settled on reducing the denominator by 10% in the calculation of prevalence estimates to compensate for RA patients who were diagnosed and seen only by private practitioners (slightly higher deduction because of the lower probability of patients treated without biologics in private practice to have been in contact with public health care also). This analysis can also be seen as a measure of sensitivity of the SHCR and our case criterion to capture biologically treated RA patients [1349 of 1455 (92.6%)].
Guidelines for biologics therapy have been continuously issued since their introduction from the Swedish Rheumatologic Society. Although some modifications have been introduced, they generally stipulate that the patient should have tried at least one or two traditional DMARDs (one being MTX) with insufficient effect or intolerance before starting a biological therapy. Toohigh systemic corticosteroid need is also a valid reason for biological treatment. All costs are tax funded, except a co-payment of 180 euros/year for all prescribed drugs.
To further evaluate the quality of the diagnostic coding of the SHCR, we also determined the proportion of prevalent RA cases (according to the SHCR) that had been treated with biologics and compared that proportion with the expected based on data from pharmaceutical sales. We also compared our estimates of disease occurrence with those from other studies of RA and with the expected age and sex patterns.
Incidence estimates for 2008
For the calendar year of 2008, we estimated the incidence of RA. We considered all patients aged 520 years who presented according to our case definition as incident cases. By 'presented' we mean having had no such diagnosis in the register in the previous five calendar years. We regarded the second visit with the RA diagnosis as the 'incidence visit', meaning that we also included patients who have had one visit with the diagnosis in 2007 but where the second visit for RA occurred in 2008. The adult population in the county of Skå ne as on 31 December 2007 served as the basis for our denominator (918 455 inhabitants aged 520 years). In order to compensate for prevalent cases (not at risk of disease), the denominator was reduced by the prevalence estimate obtained for the age and sex strata. The corresponding reduction in the denominator due to cases seen in private care was also made according to the same method as used to obtain the prevalence estimates. The study was approved by the Institutional Review Board of Lund University.
Sensitivity analyses
We performed three types of sensitivity analysis. First, we varied the proportion of cases seen only by private practitioners by adjusting the reduction in the denominator from À5 to À20%. Secondly, as there were no private rheumatologists in the two eastern districts of Skå ne, we assessed the prevalence of RA in those districts only without adjustment of the denominator. Thirdly, we also evaluated the effects on the prevalence estimates by adjusting the case criteria. We applied a less strict case criterion for RA requiring the diagnosis only once but still by a specialist in rheumatology or internal medicine. Table 2 ). The prevalence peaked at age 70-79 (women = 2.1%, men = 1.1%) years before dropping in those aged 80 years ( Fig. 1) . We also present prevalence data according to sex and by different age groups (Table  3) . The share of prevalent cases in the SHCR that had been treated with biologics (ever) due to RA was 1349 of 5546 (24.3%). The share of prevalent RA patients with ongoing biological treatment by the end of 2008 was 20%. Women aged 40-59 years were more likely to be on biologics than male RA patients of corresponding age (Fig. 2) .
In a primary sensitivity analysis, we evaluated the effects on the prevalence estimates of adjusting the denominator of the proportion (Fig. 1) . In a secondary sensitivity analysis, evaluating the prevalence of RA in the two health care districts of the county with no private rheumatologist (adult population 204 541), the prevalence (age-and sex-standardized to the county at large) 0.67% was essentially the same as the county estimate (0.66%) in support of our methodology. In the third and final sensitivity analysis, applying a less strict case criterion (only one visit required), the overall crude prevalence in the county was only modestly increased from 0.66 to 0.72%.
In 2008, the overall annual crude incidence of RA was estimated as 50/100 000 with an age-standardized estimate of 46/100 000 ( Table 2 ). The incidence of RA increased with age and peaked for women at the age of 65-79 years (crude peak incidence of 135/100 000 women per year) before declining in the most elderly women. In men, the incidence peaked in the most elderly, those aged 580 years (72/100 000 men per year; Fig. 3 ).
Discussion
The prevalence estimate of RA obtained from the SHCR, 0.66%, does not suggest a decline in prevalence in southern Sweden in the last decade [4] . Also, the age and sex characteristics of both incidence and prevalence estimates of RA are in line with estimates from other European countries and the USA in support of external validity of the register data and our case criteria [2, 3, 6, 8, [11] [12] [13] [14] [15] . Further, we observed a decline in prevalence in the most elderly, probably as a reflection of the increased morbidity and mortality in patients with RA [24] . In 1985, investigators found a prevalence of RA in Rochester, MN of 1.07%. However, data from Pima Indians and a comprehensive review of the topic on RA prevalence in the USA including still unpublished data suggest that the prevalence is declining in more recent time periods with an estimate reaching 0.6% in those aged 518 years [3, 25] . Data from Finland have suggested a similar decline [8] . More recent register data from Norfolk, UK, extrapolated to the population, suggest a crude prevalence of 0.81% in persons aged 516 years [5] . Various methodological issues, i.e. different criteria for disease classification, various degrees of selection or information bias are possible explanations of the variation in estimates. Still, ethnicity or secular trends cannot be ruled out [3, 8, 26, 27] .
Of the prevalent RA patients, by the end of 2008, women in the age category 40-49 years had the highest share with ongoing biological treatment, reaching 36% of all female RA patients in that age category. In general, the prescription of biologics was slightly more common in female patients across most age groups, confirming the notion that female RA patients have a more severe disease course [28] . As expected, the share of patients who had been prescribed biologics was the lowest among the most elderly, in view of the known increase in infectious complications with these treatments [29] .
There are two important limitations of the SHCR data we would like to point out. First, there are no strict formal guidelines for the diagnosis of RA although Swedish rheumatologists are well acquainted with and often use the ACR criteria as support for their clinical diagnosis [20] . The data are solely based on patient-driven clinical visits and the judgement of the individual physician, but in order to increase specificity of our case criteria we required the diagnosis on at least two occasions, whereof at least one should be from a specialist in rheumatology or internal medicine (or under specialty training). Thus, we cannot exclude the possibility of some under-detection due to not capturing RA patients only seen and maintained by general practitioners. Our external validation, against a treatment register with validated RA diagnoses, support high quality of the disease classification in the SHCR. Also, the prescription frequency of biologics in our prevalent RA cases (24%) matched the expected frequency of $25% for the county of Skå ne [30] . Secondly, for private care providers the diagnosis code(s) have so far not been included in the set of variables reported into the system, and patients only seen by a rheumatologist in Strengths of the register data include the prospective and continuous data collection (with diagnoses as given by physicians) covering a well-defined geographical region inhabited by a relatively large population. Both inpatient and outpatient care are included and there is a very comprehensive coverage of health care consultations by personal identification number, date of consultation and health care provider due to the publicly funded health care system and the linkage to the reimbursement system. Thus, it is a cost-and time-effective means of obtaining current future updates enabling detection of possible secular trends in disease occurrence. Further, via the personal identifier we are able to link these data to other national register resources, e.g. Social Insurance Agency data of sick leave and disability pension, which allows future studies of societal resource consumption.
In conclusion, since the mid-1990s, the prevalence of RA in southern Sweden does not seem to have declined. The proportion of prevalent RA patients who have been prescribed biologics is generally slightly higher for women with a peak between 40 and 49 years. Also, the study illustrates the potential of the SHCR, covering both inpatient and outpatient data, to provide updated prevalence and incidence estimates of clinically important diseases in a timely and cost-efficient manner. 
